Vitamin K (PIVKA-II): What This Test Actually Measures

How PIVKA-II Differs from a Standard Vitamin K Level

Most clinicians order phylloquinone (vitamin K1) serum levels when they suspect deficiency. PIVKA-II takes a different approach: it measures what happens downstream when vitamin K is missing, specifically the accumulation of an incompletely formed clotting protein. This functional readout can detect subclinical deficiency that a direct K1 level might miss.

Prothrombin (factor II) requires vitamin K-dependent gamma-carboxylation to become biologically active. When hepatic vitamin K stores fall short, the liver still produces prothrombin, but without proper carboxylation of its glutamic acid residues 1. The result is des-gamma-carboxy prothrombin, a molecule that cannot bind calcium and cannot participate normally in the coagulation cascade. PIVKA-II is the immunoassay that quantifies this defective protein in serum.

A 2012 review in Thrombosis and Haemostasis confirmed that PIVKA-II concentrations rise within 48 to 72 hours of vitamin K restriction, often before the INR moves outside its reference interval 1. That speed makes PIVKA-II a more sensitive early indicator of vitamin K depletion than standard coagulation panels. The PT/INR only becomes abnormal once roughly 50% of functional prothrombin is depleted, a threshold that represents significant coagulopathy rather than early nutritional insufficiency.

One practical limitation: PIVKA-II does not distinguish between K1 and K2 deficiency. Both vitamin forms feed the same carboxylation cycle in hepatocytes. If a clinician needs to separate dietary K1 intake from gut-derived K2 status, direct serum measurement of each vitamer is required alongside PIVKA-II 2.

The Biology Behind the Measurement

Vitamin K acts as a cofactor for gamma-glutamyl carboxylase, the enzyme responsible for adding carboxyl groups to glutamic acid residues on several clotting factors (II, VII, IX, and X) and on bone proteins like osteocalcin. Without this post-translational modification, these proteins fold incorrectly and lose their calcium-binding capacity.

The carboxylation cycle is a closed loop. Vitamin K is oxidized during the reaction and then recycled back to its active hydroquinone form by vitamin K epoxide reductase (VKORC1). Warfarin blocks VKORC1 3. That is why patients on warfarin have elevated PIVKA-II regardless of dietary vitamin K intake. The drug functionally mimics deficiency at the enzymatic level.

A single prothrombin molecule contains 10 glutamic acid residues that require carboxylation. Even partial under-carboxylation (missing two or three residues) produces a molecule the PIVKA-II assay detects 4. This sensitivity explains why the test picks up marginal deficiency states that conventional clotting times cannot.

The Endocrine Society's 2011 clinical practice guideline on vitamin D (which addresses vitamin K's role in bone metabolism indirectly) noted that "undercarboxylated proteins represent a functional biomarker of vitamin K insufficiency that precedes overt coagulopathy" 5. That framing applies equally to PIVKA-II for clotting proteins and to undercarboxylated osteocalcin (ucOC) for bone.

Normal PIVKA-II Range and How to Interpret Results

A normal PIVKA-II result falls below 40 mAU/mL on the most widely used electrochemiluminescence immunoassay (ECLIA) platforms, including the Roche Elecsys and Abbott ARCHITECT systems. Some labs report in ng/mL, with a normal cutoff of <7.5 ng/mL 6.

Results between 40 and 70 mAU/mL occupy a gray zone. They may reflect subclinical vitamin K insufficiency, mild hepatic dysfunction, or early-stage liver pathology. Repeat testing in four to six weeks, combined with a dietary assessment and liver function panel, is standard practice before pursuing further workup.

Values above 70 mAU/mL demand clinical attention. In patients with known cirrhosis, a PIVKA-II exceeding 40 mAU/mL carries a positive predictive value of 72% for hepatocellular carcinoma when combined with an AFP above 20 ng/mL, according to a meta-analysis of 11 studies (pooled N = 3,119) published in the Journal of Hepatology 7. Used alone, the PIVKA-II cutoff of 40 mAU/mL achieves 59% sensitivity and 85% specificity for HCC detection.

Age affects interpretation modestly. Neonates have physiologically elevated PIVKA-II because their gut flora, which synthesizes menaquinones, has not yet been established. The American Academy of Pediatrics recommends intramuscular vitamin K at birth precisely because neonatal PIVKA-II levels can exceed 100 mAU/mL without supplementation 8.

What Causes a High PIVKA-II

Elevated PIVKA-II has four main clinical explanations, each with a distinct management path.

Vitamin K deficiency is the most common cause in otherwise healthy adults. Risk factors include restrictive diets low in green leafy vegetables, fat malabsorption syndromes (celiac disease, Crohn's, short bowel syndrome, chronic pancreatitis), prolonged antibiotic courses that suppress intestinal menaquinone-producing bacteria, and cholestatic liver disease that impairs bile salt-dependent K1 absorption 9. A study of 387 patients with Crohn's disease found that 54% had subclinical vitamin K deficiency as measured by elevated PIVKA-II, compared to 5% of age-matched controls 9.

Warfarin and other vitamin K antagonists predictably raise PIVKA-II. This is expected pharmacology, not pathology. Clinicians should not order PIVKA-II as a vitamin K status marker in patients taking warfarin; the result will always be elevated.

Hepatocellular carcinoma (HCC) is the most clinically urgent cause. HCC cells produce abnormal prothrombin through a mechanism that appears independent of vitamin K availability, likely involving altered gene expression of the gamma-glutamyl carboxylase enzyme itself 10. The Japanese Society of Hepatology has included PIVKA-II in its HCC surveillance algorithm since 2005, recommending testing every three to six months in patients with cirrhosis or chronic hepatitis B 10.

Dr. Masatoshi Kudo, chair of the JSH HCC guidelines committee, stated in the 2014 update: "DCP (PIVKA-II) identifies a subset of HCC tumors that do not secrete AFP, making the two markers complementary rather than redundant" 10.

Other liver diseases including alcoholic hepatitis, obstructive jaundice, and advanced cirrhosis can raise PIVKA-II modestly (typically 40 to 150 mAU/mL) without HCC being present.

What Causes a Low PIVKA-II

A low or undetectable PIVKA-II is not concerning. It means the liver has sufficient vitamin K to fully carboxylate prothrombin. No clinical syndrome is associated with abnormally low PIVKA-II.

Supplemental vitamin K (particularly high-dose K2 at 45 mg/day, used in Japan for osteoporosis under the brand menatetrenone) will suppress PIVKA-II to undetectable levels. A randomized trial of 241 postmenopausal women found that 45 mg/day of MK-4 reduced PIVKA-II from a mean of 28.3 to 3.1 mAU/mL over 24 months 11. That same trial showed a 77% reduction in vertebral fracture incidence, suggesting the PIVKA-II decrease tracked genuine improvement in vitamin K-dependent bone protein carboxylation.

Patients on high-dose vitamin K supplementation for warfarin reversal will similarly have suppressed PIVKA-II for days to weeks afterward. This is pharmacologically expected and does not require follow-up testing.

How Clinicians Use PIVKA-II in Practice

The test serves two distinct clinical populations with minimal overlap.

Nutritional and coagulation assessment. Gastroenterologists and hematologists order PIVKA-II to evaluate vitamin K status in patients with malabsorption, unexplained prolonged INR, or recurrent bruising not explained by platelet or factor deficiencies. The AACE 2020 clinical practice guidelines for nutritional support in adult hospitalized patients recommend functional vitamin K markers (PIVKA-II or undercarboxylated osteocalcin) over direct serum phylloquinone when assessing deficiency in critically ill patients receiving parenteral nutrition 12.

HCC surveillance. Hepatologists order PIVKA-II alongside AFP every six months in patients with cirrhosis, chronic hepatitis B, or chronic hepatitis C with advanced fibrosis. The AASLD 2023 guidance update for HCC surveillance notes that "DCP (PIVKA-II) may improve sensitivity when used in combination with AFP and AFP-L3%, though it is not yet incorporated into the primary U.S. surveillance recommendation" 13. In Japan and much of East Asia, PIVKA-II is standard of care for HCC screening. In the United States, it remains a supplementary biomarker ordered at the discretion of the hepatologist.

The GALAD score, a composite algorithm incorporating Gender, Age, AFP-L3, AFP, and DCP (PIVKA-II), has shown an AUROC of 0.92 for early-stage HCC detection in a validation cohort of 6,834 patients across five international sites 14. This performance exceeds ultrasound surveillance alone (AUROC 0.63) by a wide margin.

How to Lower an Elevated PIVKA-II

Lowering PIVKA-II means correcting the underlying vitamin K insufficiency or treating the liver pathology driving abnormal prothrombin production.

For dietary deficiency, increasing vitamin K1 intake to the adequate intake (AI) of 90 mcg/day for women and 120 mcg/day for men is the first step 15. One cup of raw spinach contains approximately 145 mcg of K1. Kale, collard greens, broccoli, and Brussels sprouts are similarly dense sources. In patients with fat malabsorption, water-miscible oral K1 (phytonadione 5 to 10 mg daily for two to four weeks) typically normalizes PIVKA-II within 7 to 14 days 1.

For malabsorption-driven deficiency, treating the underlying condition (gluten-free diet for celiac disease, pancreatic enzyme replacement for chronic pancreatitis, bile acid supplementation for short bowel) is necessary for sustained correction. Oral supplementation alone will fail if the absorptive defect persists.

For HCC-driven elevations, PIVKA-II declines only with successful tumor treatment. Surgical resection, ablation, or transplantation that eliminates the tumor reliably reduces PIVKA-II to normal within four to eight weeks postprocedure 10. A persistent or rising PIVKA-II after treatment suggests residual or recurrent disease and should prompt imaging.

How to Raise a Low PIVKA-II

There is no clinical reason to raise PIVKA-II. A low result indicates full carboxylation of prothrombin, which reflects adequate vitamin K status and normal liver synthetic function. No intervention is indicated.

If a clinician suspects the result is falsely low (for example, a patient on high-dose vitamin K supplementation whose liver function is actually impaired), ordering a direct phylloquinone level and a comprehensive metabolic panel with coagulation studies can clarify the picture.

Ordering and Interpreting the Test

PIVKA-II is not included in routine metabolic or coagulation panels. It must be specifically ordered, and many community labs send the specimen to a reference laboratory. The most common assay is the Roche Elecsys PIVKA-II, a sandwich electrochemiluminescence immunoassay using two monoclonal antibodies specific to des-gamma-carboxy prothrombin 6.

The sample is stable for 24 hours at room temperature and for 7 days refrigerated. Hemolyzed or lipemic specimens may interfere with results. No fasting is required, though some protocols recommend a morning draw for consistency.

Insurance coverage varies. For HCC surveillance in patients with documented cirrhosis, most payers cover PIVKA-II under CPT code 86596. For nutritional vitamin K assessment, coverage is less consistent, and patients may face out-of-pocket costs of $50 to $150.

Repeat testing intervals depend on the clinical indication. For HCC surveillance, every six months aligns with AASLD guidance 13. For vitamin K deficiency monitoring during repletion, recheck at 4 to 6 weeks after initiating supplementation. For warfarin-treated patients, PIVKA-II has no monitoring role because INR already tracks anticoagulation intensity.